Legislative Policy Panel Acts on Opioid Treatment Policies

The MHA Legislative Policy Panel met virtually March 12 to develop recommendations on legislative and policy issues impacting Michigan hospitals. The MHA advocacy team provided important updates to the panel on healthcare activities at both the federal and state levels.

Adam Carlson, senior vice president, advocacy, shared the federal update, recapping the activities of the Trump administration since inauguration. Topics included a review of several healthcare-related executive orders, federal agency appointments and proposed Medicaid funding cuts.

Elizabeth Kutter, senior director, advocacy, then provided the panel with a state legislative update, recapping the recent passage of 340B contract pharmacy legislation in the Senate and the recently revised Earned Sick Time Act. Senate Bill (SB) 94, sponsored by Sen. Sam Singh (D-East Lansing), passed the Senate 33-3, with overwhelming bipartisan support, on March 6, which safeguards the 340B program in Michigan, ensuring cost savings and preserving access to affordable healthcare services in both urban and rural Michigan communities. The bill is paired with SB 95, sponsored by Sen. Jonathan Lindsey (R-Allen), which requires hospital compliance with federal cost transparency laws.

John Karasinski, senior director, communications, discussed the public communications strategies supporting Medicaid and 340B efforts. Panel members were encouraged to visit the MHA’s Legislative Action Center and to use the action alerts for both topics.

The Panel chose to act on two issues, making recommendations related to opioid treatments. The first recommendation directs the MHA to support efforts to eliminate prior authorization requirements for buprenorphine. The second recommendation is for the MHA to work with state agencies on state regulatory requirements for opioid treatment programs.

For more information on the MHA Legislative Policy Panel, members may contact Adam Carlson at the MHA.

Senate Introduces 340B Hospital Protections; MHA Testifies on IMLC

The Senate introduced MHA-driven legislation protecting the 340B program and the House Health Policy Committee heard testimony on the Interstate Medical Licensure Compact (IMLC) legislation during the week of Feb. 17.

The Senate introduced Senate Bill (SB) 94, sponsored by Sen. Sam Singh (D-East Lansing), on Feb. 20. This legislation ensures protections from drug manufacturer overreach for hospitals and community health clinics participating in the 340B program in Michigan. The bill is vital for hospitals that serve vulnerable populations, helping them stretch scarce resources to care for more patients. SB 94 safeguards the program, ensuring cost savings and preserving access to affordable healthcare services in both urban and rural Michigan communities. Further, this legislation adds first-of-its-kind pharmaceutical manufacturer transparency requirements, making Michigan’s legislation the strongest in the nation.

The Senate paired SB 94 with SB 95, sponsored by Sen. Jonathan Lindsey (R-Allen), which requires hospital compliance with federal cost transparency laws. The MHA continues to advocate for the 340B program and support Michigan hospitals’ efforts to expand access to quality, community-based care. Members are encouraged to contact their lawmakers in support of this legislation.

In addition, the House Health Policy Committee heard testimony on House Bill (HB) 4032, introduced by Rep. Rylee Linting (R-Grosse Ile), during the committee’s first meeting of the new session. Adam Carlson, senior vice president, Advocacy, MHA, testified in support of the legislation to eliminate the sunset on the interstate medical licensure compact, which streamlines the licensing process and allows physicians licensed in one state to practice in multiple, participating states.

By removing additional licensing requirements for physicians seeking to practice across state lines, patients experience increased access to care, especially in rural and underserved areas, by physicians included in the compact. States involved in the compact can share disciplinary and investigative information through the state medical board to strengthen public protection for patients and the program. Michigan’s participation in the compact is currently set to expire March 28, 2025. The MHA supports this legislation and is working quickly with legislators to move it through the legislative process before the compact’s current expiration date.

Members with questions may contact Adam Carlson at the MHA.